06.20.2023
Diagnostics
$1,556,119.00
36 months
The EXTENT Study (Calculating the LEmann indeX using inTEstiNal ulTrasound)
Avoiding progressive bowel damage is a major goal in CD treatment and endpoints reflecting this outcome are needed in clinical trials to aid in the development of drugs that can slow the progression of the disease. If successful, this study will validate the use of low-cost, patient-friendly IUS in the calculation of the LI, making the measurement of cumulative bowel damage a viable and accessible outcome in the future evaluation of novel disease-modifying therapeutics